Braeckman RA, Stirtan WG, Soni PN. Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults. Drugs R D. 2014;14:159-164.
Free:
http://link.springer.com/article/10.1007%2Fs40268-014-0053-9

Braeckman R, Bays HE, Ballantyne CM, Stirtan WG, Soni PN. Pharmacokinetic and triglyceride-lowering pharmacodynamic effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) across clinical studies [abstract]. Circulation. 2013;128:A19343.

Bays HE, Ballantyne CM, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. AMR101, a pure-EPA omega-3 fatty acid, lowers triglycerides in patients with very high triglycerides without raising LDL-C: the MARINE study [abstract]. J Clin Lipidol. 2011;5:205.

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. The effect of two doses of AMR101 on fasting serum triglycerides and other lipid parameters in statin-treated patients with persistent high triglycerides (≥200 and <500 mg/dL): the ANCHOR study [abstract]. J Clin Lipidol. 2012;6:279-280.

Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. AMR101, a pure ethyl eicosapentaenoic acid omega-3 fatty acid: effects on inflammation-associated end points from the MARINE and ANCHOR study [abstract]. J Clin Lipidol. 2012;6:279.

Braeckman RA, Stirtan WG, Soni PN. Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetics and anticoagulation pharmacodynamics in healthy subjects [abstract]. J Clin Lipidol. 2013;7:270.

Braeckman RA, Stirtan WG, Soni PN. Phase 1 study of the effect of icosapent ethyl on atorvastatin pharmacokinetics in healthy subjects [abstract]. J Clin Lipidol. 2013;7:269-270.

Ballantyne CM, Bays HE, Braeckman RA, Stirtan WG, Doyle RT Jr, Juliano R, Soni PN. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients from the MARINE and ANCHOR studies [abstract]. J Clin Lipidol. 2014;8:313-314.